Forbes January 16, 2024
Topline
The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusion-dependent beta thalassemia—marking the second major U.S. regulatory approval for the emerging gene-editing technology.
Key Facts
What To Watch For
Vertex says it’s engaging with experienced hospitals to establish “a network of independently operated, authorized treatment centers” throughout the U.S. to administer Casgevy. There are currently nine activated treatment centers in the U.S., but more will be activated in the coming weeks, Vertex said in a press release. The administration of Casgevy requires experience in stem cell transplantation.
Key Background
CRISPR, or “clustered regularly interspaced short palindromic repeats,” is seen as...
Today's Sponsors
Today's Sponsor